5,029 shares in Danaher Co. (NYSE:DHR) bought by &Partners

&Partners bought a new stake in shares of Danaher Co. (NYSE:DHR – Free Report) during the second quarter, HoldingsChannel.com reports. The firm purchased 5,029 shares of the conglomerate’s stock, valued at approximately $1,257,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Wellington Management Group LLP boosted its stake in Danaher by 12.0% in the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after purchasing an additional 2,998,161 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Danaher by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after acquiring an additional 1,619,586 shares during the period. Capital International Investors lifted its position in shares of Danaher by 9.1% in the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after acquiring an additional 1,334,781 shares during the period. actions during the period. Finally, Norges Bank acquired a new stake in shares of Danaher during the fourth quarter valued at approximately $1,752,382,000. Institutional investors and hedge funds own 79.05% of the company’s shares.

Danaher price performance

Shares of DHR stock opened at $269.48 on Friday. The firm has a market cap of $199.60 billion, a price-to-earnings ratio of 45.67, a PEG ratio of 4.62 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43, and a debt-to-equity ratio of 0.33. The stock has a 50-day moving average price of $258.72 and a 200-day moving average price of $254.34.

Danaher (NYSE:DHR – Get Free Report ) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. In the same quarter last year, the company earned $2.05 per share. The company’s revenue was down 2.9% compared to the same quarter last year. Research analysts expect Danaher Co. to post 7.59 EPS for the current year.

Analysts on Wall Street are forecasting an increase

A number of research firms have weighed in on DHR. Evercore ISI cut their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. TD Cowen boosted their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Robert W. Baird boosted their price target on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Finally, Jefferies Financial Group initiated coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $276.88, based on data from MarketBeat.com.

Read our latest research report on Danaher

Insiders place their bets

In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The sale was disclosed in a legal filing with the SEC, which is accessible via this hyperlink. In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,707 shares of company stock worth $10,786,944. 11.10% of shares are currently owned by corporate insiders.

About Danaher

(Free report)

Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services worldwide. The Biotechnology segments provide bioprocess technologies, consumables and services that advance, accelerate and integrate drug development and manufacturing; cell line and cell culture media development services; cell culture media, process fluids and manufacturing buffers, chromatography resins, filtration technologies, aseptic fill finishing; disposable hardware and supplies and services such as design and installation of complete manufacturing suites; laboratory filtration, separation and purification; laboratory-scale protein purification and analytical tools; reagents, membranes and services; and filtration solutions for health care.

Featured stories

Want to see what other hedge funds own DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Danaher Co. (NYSE:DHR – Free Report).

Get news and reviews for Danaher Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Danaher and related companies with MarketBeat.com’s FREE daily email newsletter.